Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19

British Journal of Clinical Pharmacology

Volumn 77, Issue 3, 2014, Pages 554-570

  Ke, Alice Ban ^a,b   Nallani, Srikanth C ^b   Zhao, Ping ^b   Rostami Hodjegan, Amin ^c,d   Unadkat, Jashvant D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d CERTARA UK LIMITED   (United Kingdom)

Author keywords

CYP2B6; CYP2C19; CYP2C9; PBPK; pharmacokinetics; pregnancy

Indexed keywords

CYP2B6; CYP2C19; CYP2C9; PBPK; PHARMACOKINETICS; PREGNANCY;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; COMPUTER SIMULATION; FEMALE; GLYBURIDE; HEPATOCYTES; HUMANS; METHADONE; MICE; MODELS, BIOLOGICAL; PREGNANCY; SUBSTRATE SPECIFICITY; WORKFLOW;

EID: 84891847118     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12207     Document Type: Article

References (72)

1. van Hasselt JG, Andrew MA, Hebert MF, Tarning J, Vicini P, Mattison DR,. The status of pharmacometrics in pregnancy: highlights from the 3(rd) American Conference on Pharmacometrics. Br J Clin Pharmacol 2012; 74: 932-939.
2. Pond SM, Kreek MJ, Tong TG, Raghunath J, Benowitz NL,. Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther 1985; 233: 1-6.
3. Shiran MR, Lennard MS, Iqbal MZ, Lagundoye O, Seivewright N, Tucker GT, Rostami-Hodjegan A,. Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment. J Clin Psychopharmacol 2012; 32: 666-671.
4. Kirchheiner J, Brockmoller J, Meineke I, Bauer S, Rohde W, Meisel C, Roots I,. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 2002; 71: 286-296.
5. Hebert MF, Ma X, Naraharisetti SB, Krudys KM, Umans JG, Hankins GD, Caritis SN, Miodovnik M, Mattison DR, Unadkat JD, Kelly EJ, Blough D, Cobelli C, Ahmed MS, Snodgrass WR, Carr DB, Easterling TR, Vicini P,. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther 2009; 85: 607-614.
6. Hodge LS, Tracy TS,. Alterations in drug disposition during pregnancy: implications for drug therapy. Expert Opin Drug Metab Toxicol 2007; 3: 557-571.
7. Jeong H,. Altered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymes. Expert Opin Drug Metab Toxicol 2010; 6: 689-699.
8. Rowland M, Peck C, Tucker G,. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011; 51: 45-73.
9. Jamei M, Dickinson GL, Rostami-Hodjegan A,. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet 2009; 24: 53-75.
10. Lu G, Abduljalil K, Jamei M, Johnson TN, Rostami-Hodjegan A,. A pregnancy physiologically-based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP3A4 and CYP2D6. Br J Clin Pharmacol 2012; 74: 873-885.
11. Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H,. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet 2012; 51: 365-396.
12. Ke AB, Nallan SC, Zhao P, Rostami-Hodjegan A, Unadkat JD,. A PBPK model to predict disposition of CYP3A-metabolized drugs in pregnant women: verification and discerning the site of CYP3A induction. Clin Pharmacol Ther 2012; 1. Available at http://www.nature.com/psp/journal/v1/n9/index.html (last accessed 6 August 2013).
13. Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Isoherranen N, Unadkat JD,. A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. Drug Metab Dispos 2013; 41: 801-813.
14. Cressey TR, Best BM, Achalapong J, Stek A, Wang J, Chotivanich N, Yuthavisuthi P, Suriyachai P, Prommas S, Shapiro DE, Watts DH, Smith E, Capparelli E, Kreitchmann R, Mirochnick M,. Reduced indinavir exposure during pregnancy. Br J Clin Pharmacol 2013; 76: 475-483.
15. Tomson T, Lindbom U, Ekqvist B, Sundqvist A,. Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin. Epilepsia 1994; 35: 122-130.
16. Tomson T, Lindbom U, Ekqvist B, Sundqvist A,. Disposition of carbamazepine and phenytoin in pregnancy. Epilepsia 1994; 35: 131-135.
17. McGready R, Stepniewska K, Edstein MD, Cho T, Gilveray G, Looareesuwan S, White NJ, Nosten F,. The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. Eur J Clin Pharmacol 2003; 59: 545-552.
18. McGready R, Stepniewska K, Seaton E, Cho T, Cho D, Ginsberg A, Edstein MD, Ashley E, Looareesuwan S, White NJ, Nosten F,. Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. Eur J Clin Pharmacol 2003; 59: 553-557.
19. Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED,. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 2008; 108: 363-374.
20. Kharasch ED, Hoffer C, Whittington D, Walker A, Bedynek PS,. Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir. Anesthesiology 2009; 110: 660-672.
21. Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F,. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol 2000; 50: 427-440.
22. Eap CB, Buclin T, Baumann P,. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 2002; 41: 1153-1193.
23. Totah RA, Allen KE, Sheffels P, Whittington D, Kharasch ED,. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther 2007; 321: 389-399.
24. Cao YJ, Smith PF, Wire MB, Lou Y, Lancaster CT, Causon RC, Bigelow GE, Martinez E, Fuchs EJ, Radebaugh C, McCabe S, Hendrix CW,. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects. Pharmacotherapy 2008; 28: 863-874.
25. Liu P, Foster G, Labadie R, Somoza E, Sharma A,. Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy. Antimicrob Agents Chemother 2007; 51: 110-118.
26. Kharasch ED, Hoffer C, Whittington D, Sheffels P,. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 2004; 76: 250-269.
27. Garrido MJ, Troconiz IF,. Methadone: a review of its pharmacokinetic/ pharmacodynamic properties. J Pharmacol Toxicol Methods 1999; 42: 61-66.
28. Boulton DW, Arnaud P, DeVane CL,. Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clin Pharmacol Ther 2001; 70: 48-57.
29. Dickmann LJ, Isoherranen N,. Quantitative prediction of CYP2B6 induction by estradiol during pregnancy, potential explanation for increased methadone clearance during pregnancy. Drug Metab Dispos 2012; 41: 270-274.
30. Choi SY, Koh KH, Jeong H,. Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos 2012; 41: 263-269.
31. Product label for Activella® (estradiol/norethindrone acetate) tablets. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/ 022001lbl.pdf (last accessed 5 August 2013).
32. GLIMEL® (glibenclamide) Tablets Product Label. Available at http://www.pbs.gov.au/meds%2Fpi%2Fafpglime10808.pdf (last accessed 5 August 2013).
33. Zheng HX, Huang Y, Frassetto LA, Benet LZ,. Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther 2009; 85: 78-85.
34. Zharikova OL, Fokina VM, Nanovskaya TN, Hill RA, Mattison DR, Hankins GD, Ahmed MS,. Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide. Biochem Pharmacol 2009; 78: 1483-1490.
35. Zhou L, Naraharisetti SB, Liu L, Wang H, Lin YS, Isoherranen N, Unadkat JD, Hebert MF, Mao Q,. Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharm Drug Dispos 2010; 31: 228-242.
36. Appel S, Rufenacht T, Kalafsky G, Tetzloff W, Kallay Z, Hitzenberger G, Kutz K,. Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus. Am J Cardiol 1995; 76: 29A-32A.
37. Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT,. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 2002; 72: 326-332.
38. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, Sawada Y,. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 2005; 33: 518-523.
39. Hirano M, Maeda K, Shitara Y, Sugiyama Y,. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 2006; 34: 1229-1236.
40. Naritomi Y, Terashita S, Kagayama A,. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate. Xenobiotica 2004; 34: 415-427.
41. Varma MV, Lai Y, Feng B, Litchfield J, Goosen TC, Bergman A,. Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharm Res 2012; 29: 2860-2873.
42. Funck-Brentano C, Becquemont L, Lenevu A, Roux A, Jaillon P, Beaune P,. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J Pharmacol Exp Ther 1997; 280: 730-738.
43. Product label for MALARONE® (250 mg Atovaquone + 100 mg Proguanil Hydrochloride) Tablets. Available at http://www.gsk.ca/english/docs-pdf/ Malarone-PM-EN-20071102.pdf (last accessed 5 August 2013).
44. Wattanagoon Y, Taylor RB, Moody RR, Ochekpe NA, Looareesuwan S, White NJ,. Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. Br J Clin Pharmacol 1987; 24: 775-780.
45. Almond LM, Yang J, Jamei M, Tucker GT, Rostami-Hodjegan A,. Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. Curr Drug Metab 2009; 10: 420-432.
46. Blum RA, Wilton JH, Hilligoss DM, Gardner MJ, Henry EB, Harrison NJ, Schentag JJ,. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 1991; 49: 420-425.
47. Yerby MS, Friel PN, McCormick K, Koerner M, Van Allen M, Leavitt AM, Sells CJ, Yerby JA,. Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding. Epilepsy Res 1990; 5: 223-228.
48. Lau YY, Huang Y, Frassetto L, Benet LZ,. effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 2007; 81: 194-204.
49. Anderson GD,. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005; 44: 989-1008.
50. O'Leary P, Boyne P, Flett P, Beilby J, James I,. Longitudinal assessment of changes in reproductive hormones during normal pregnancy. Clin Chem 1991; 37: 667-672.
51. Wolff K, Boys A, Rostami-Hodjegan A, Hay A, Raistrick D,. Changes to methadone clearance during pregnancy. Eur J Clin Pharmacol 2005; 61: 763-768.
52. Jarvis MA, Wu-Pong S, Kniseley JS, Schnoll SH,. Alterations in methadone metabolism during late pregnancy. J Addict Dis 1999; 18: 51-61.
53. Siccardi M, Almond L, Schipani A, Csajka C, Marzolini C, Wyen C, Brockmeyer NH, Boffito M, Owen A, Back D,. Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model. Clin Pharmacol Ther 2012; 92: 494-502.
54. Cressey TR, Stek A, Capparelli E, Bowonwatanuwong C, Prommas S, Sirivatanapa P, Yuthavisuthi P, Neungton C, Huo Y, Smith E, Best BM, Mirochnick M,. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr 2012; 59: 245-252.
55. Mwinyi J, Cavaco I, Pedersen RS, Persson A, Burkhardt S, Mkrtchian S, Ingelman-Sundberg M,. Regulation of CYP2C19 expression by estrogen receptor alpha: implications for estrogen-dependent inhibition of drug metabolism. Mol Pharmacol 2010; 78: 886-894.
56. Lim ML, Min SS, Eron JJ, Bertz RJ, Robinson M, Gaedigk A, Kashuba AD,. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr 2004; 36: 1034-1040.
57. Randinitis EJ, Alvey CW, Koup JR, Rausch G, Abel R, Bron NJ, Hounslow NJ, Vassos AB, Sedman AJ,. Drug interactions with clinafloxacin. Antimicrob Agents Chemother 2001; 45: 2543-2552.
58. Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A,. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol 2003; 56: (Suppl 1): 37-44.
59. Rydberg T, Jonsson A, Melander A,. Comparison of the kinetics of glyburide and its active metabolites in humans. J Clin Pharm Ther 1995; 20: 283-295.
60. Pollex EK, Anger G, Hutson J, Koren G, Piquette-Miller M,. Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism. Drug Metab Dispos 2010; 38: 740-744.
61. Ke AB, Nallan SC, Zhao P, Rostami-Hodjegan A, Isoherranen N, Unadkat JD,. A PBPK model to predict disposition of P450 2D6 and P450 1A2 metabolized drugs in pregnant women. Drug Metab Dispos 2013; 41: 801-813.
62. Gerber JG, Rosenkranz S, Segal Y, Aberg J, D'Amico R, Mildvan D, Gulick R, Hughes V, Flexner C, Aweeka F, Hsu A, Gal J,. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J Acquir Immune Defic Syndr 2001; 27: 153-160.
63. Eap CB, Cuendet C, Baumann P,. Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of alpha 1-acid glycoprotein. Clin Pharmacol Ther 1990; 47: 338-346.
64. Dale O, Sheffels P, Kharasch ED,. Bioavailabilities of rectal and oral methadone in healthy subjects. Br J Clin Pharmacol 2004; 58: 156-162.
65. Wolff K, Rostami-Hodjegan A, Hay AW, Raistrick D, Tucker G,. Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. Addiction 2000; 95: 1771-1783.
66. Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A,. Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 2007; 8: 676-684.
67. Rodgers T, Rowland M,. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res 2007; 24: 918-933.
68. Savolainen J, Jarvinen K, Taipale H, Jarho P, Loftsson T, Jarvinen T,. Co-administration of a water-soluble polymer increases the usefulness of cyclodextrins in solid oral dosage forms. Pharm Res 1998; 15: 1696-1701.
69. Obach RS, Lombardo F, Waters NJ,. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 2008; 36: 1385-1405.
70. Rydberg T, Jonsson A, Karlsson MO, Melander A,. Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 1997; 43: 373-381.
71. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivisto KT,. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther 2001; 69: 400-406.
72. Karim A, Laurent A, Munsaka M, Wann E, Fleck P, Mekki Q,. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol 2009; 49: 1210-1219